67. P. Mansfield, Snapshot magnetic resonance imaging (nobel lecture). Angew. Chem. Int. Ed.
Engl. 43(41), 5456–5464 (2004)
68. P.E.J. Caravan, T.J. McMurry, R.B. Lauffer, Gadolinium(III) chelates as MRI contrast
agents: structure, dynamics, and applications. Chem. Rev. 99(9), 2293–2352 (1999)
69. G.J.M.W. Strijkers, G.A. van Tilborg, K. Nicolay, MRI contrast agents: current status and
future perspectives. Anticancer Agents Med. Chem. 7(3), 291–305 (2007)
70. S. Kanakia, J.D. Toussaint, S.M. Chowdhury, G. Lalwani, T. Tembulkar, T. Button et al.,
Physicochemical characterization of a novel graphene-based magnetic resonance imaging
contrast agent. Int J Nanomedicine. 8, 2821–2833 (2013)
71. A. Gizzatov, V. Keshishian, A. Guven, A.M. Dimiev, F. Qu, R. Muthupillai et al.,
Enhanced MRI relaxivity of aquated Gd3
+ ions by carboxyphenylated water-dispersed
graphene nanoribbons. Nanoscale 6(6), 3059–3063 (2014)
72. H.B. Na, I.C. Song, T. Hyeon, Inorganic nanoparticles for MRI contrast aAgents. Adv.
Mater. 21(21), 2133–2148 (2009)
73. H. Li, J.M. Melnyczuk, L.I. Lewis, S. Palchoudhury, J. Wu, P. Nagappan et al., Selectively
self-assembling graphene nanoribbons with shaped iron oxide nanoparticles. RSC Adv. 4
(62), 33127 (2014)
74. W. Chen, P. Yi, Y. Zhang, L. Zhang, Z. Deng, Z. Zhang, Composites of
aminodextran-coated Fe 3 O 4 nanoparticles and graphene oxide for cellular magnetic
resonance imaging. ACS Appl. Mater. Interfaces 3(10), 4085–4091 (2011)
75. X. Shi, H. Gong, Y. Li, C. Wang, L. Cheng, Z. Liu, Graphene-based magnetic plasmonic
nanocomposite for dual bioimaging and photothermal therapy. Biomaterials 34(20), 4786–
4793 (2013)
76. E. Peng, E.S.G. Choo, P. Chandrasekharan, C.-T. Yang, J. Ding, K.-H. Chuang et al.,
Synthesis of manganese ferrite/graphene oxide nanocomposites for biomedical applications.
Small 8(23), 3620–3630 (2012)
77. M.L. Chen, L.M. Shen, S. Chen, H. Wang, X.W. Chen, J.H. Wang, In situ growth of
b-FeOOH nanorods on graphene oxide with ultra-high relaxivity for in vivo magnetic
resonance imaging and cancer therapy. J. Mater. Chem. B Biol. Med. 1, 2582–2589 (2013)
78. Y. Wang, R. Huang, G. Liang, Z. Zhang, P. Zhang, S. Yu et al., MRI-visualized,
dual-targeting, combined tumor therapy using magnetic graphene-based mesoporous silica.
Small 10(1), 109–116 (2014)
79. K. Dey, A. Ghosh, P. Modak, A. Indra, S. Majumdar, S. Giri, Tuning of multiferroic orders
correlated to oxygen stoichiometry in magnetite films. Appl. Phys. Lett. 105(14), 142905
(2014)
80. J. Lin, X. Chen, P. Huang, Graphene-based nanomaterials for bioimaging. Adv. Drug Deliv.
Rev. 105, 242–254 (2016)
81. D.W. Hwang, Radio-graphene in theranostic perspectives. Nucl. Med. Mol. Imaging. 51,
1–5 (2016)
82. J.M. Craft, R.A. De Silva, K.A. Lears, R. Andrews, K. Liang, S. Achilefu et al., In vitro and
in vivo evaluation of a
64
Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in
gastrin-releasing peptide receptor expressing prostate cancer. Nucl. Med. Biol. 39, 609–
616 (2012)
83. C.M. Kang, S.M. Kim, H.J. Koo, M.S. Yim, K.H. Lee, E.K. Ryu et al., In vivo
characterization of
68
Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in
U87MG tumor xenograft models. Eur. J. Nucl. Med. Mol. Imaging 40, 198–206 (2013)
84. C.J. Choy, X. Ling, J.J. Geruntho, S.K. Beyer, J.D. Latoche, B. Langton-Webster et al.,
177
Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on
biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics 7,
1928–1939 (2017)
85. J.P. Meyer, P. Adumeau, J.S. Lewis, B.M. Zeglis, Click chemistry and radiochemistry: the
first 10 years. Bioconjug. Chem. 27, 2791–2807 (2016)
102
J. M. Yoo et al.
Engl. 43(41), 5456–5464 (2004)
68. P.E.J. Caravan, T.J. McMurry, R.B. Lauffer, Gadolinium(III) chelates as MRI contrast
agents: structure, dynamics, and applications. Chem. Rev. 99(9), 2293–2352 (1999)
69. G.J.M.W. Strijkers, G.A. van Tilborg, K. Nicolay, MRI contrast agents: current status and
future perspectives. Anticancer Agents Med. Chem. 7(3), 291–305 (2007)
70. S. Kanakia, J.D. Toussaint, S.M. Chowdhury, G. Lalwani, T. Tembulkar, T. Button et al.,
Physicochemical characterization of a novel graphene-based magnetic resonance imaging
contrast agent. Int J Nanomedicine. 8, 2821–2833 (2013)
71. A. Gizzatov, V. Keshishian, A. Guven, A.M. Dimiev, F. Qu, R. Muthupillai et al.,
Enhanced MRI relaxivity of aquated Gd3
+ ions by carboxyphenylated water-dispersed
graphene nanoribbons. Nanoscale 6(6), 3059–3063 (2014)
72. H.B. Na, I.C. Song, T. Hyeon, Inorganic nanoparticles for MRI contrast aAgents. Adv.
Mater. 21(21), 2133–2148 (2009)
73. H. Li, J.M. Melnyczuk, L.I. Lewis, S. Palchoudhury, J. Wu, P. Nagappan et al., Selectively
self-assembling graphene nanoribbons with shaped iron oxide nanoparticles. RSC Adv. 4
(62), 33127 (2014)
74. W. Chen, P. Yi, Y. Zhang, L. Zhang, Z. Deng, Z. Zhang, Composites of
aminodextran-coated Fe 3 O 4 nanoparticles and graphene oxide for cellular magnetic
resonance imaging. ACS Appl. Mater. Interfaces 3(10), 4085–4091 (2011)
75. X. Shi, H. Gong, Y. Li, C. Wang, L. Cheng, Z. Liu, Graphene-based magnetic plasmonic
nanocomposite for dual bioimaging and photothermal therapy. Biomaterials 34(20), 4786–
4793 (2013)
76. E. Peng, E.S.G. Choo, P. Chandrasekharan, C.-T. Yang, J. Ding, K.-H. Chuang et al.,
Synthesis of manganese ferrite/graphene oxide nanocomposites for biomedical applications.
Small 8(23), 3620–3630 (2012)
77. M.L. Chen, L.M. Shen, S. Chen, H. Wang, X.W. Chen, J.H. Wang, In situ growth of
b-FeOOH nanorods on graphene oxide with ultra-high relaxivity for in vivo magnetic
resonance imaging and cancer therapy. J. Mater. Chem. B Biol. Med. 1, 2582–2589 (2013)
78. Y. Wang, R. Huang, G. Liang, Z. Zhang, P. Zhang, S. Yu et al., MRI-visualized,
dual-targeting, combined tumor therapy using magnetic graphene-based mesoporous silica.
Small 10(1), 109–116 (2014)
79. K. Dey, A. Ghosh, P. Modak, A. Indra, S. Majumdar, S. Giri, Tuning of multiferroic orders
correlated to oxygen stoichiometry in magnetite films. Appl. Phys. Lett. 105(14), 142905
(2014)
80. J. Lin, X. Chen, P. Huang, Graphene-based nanomaterials for bioimaging. Adv. Drug Deliv.
Rev. 105, 242–254 (2016)
81. D.W. Hwang, Radio-graphene in theranostic perspectives. Nucl. Med. Mol. Imaging. 51,
1–5 (2016)
82. J.M. Craft, R.A. De Silva, K.A. Lears, R. Andrews, K. Liang, S. Achilefu et al., In vitro and
in vivo evaluation of a
64
Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in
gastrin-releasing peptide receptor expressing prostate cancer. Nucl. Med. Biol. 39, 609–
616 (2012)
83. C.M. Kang, S.M. Kim, H.J. Koo, M.S. Yim, K.H. Lee, E.K. Ryu et al., In vivo
characterization of
68
Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in
U87MG tumor xenograft models. Eur. J. Nucl. Med. Mol. Imaging 40, 198–206 (2013)
84. C.J. Choy, X. Ling, J.J. Geruntho, S.K. Beyer, J.D. Latoche, B. Langton-Webster et al.,
177
Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on
biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics 7,
1928–1939 (2017)
85. J.P. Meyer, P. Adumeau, J.S. Lewis, B.M. Zeglis, Click chemistry and radiochemistry: the
first 10 years. Bioconjug. Chem. 27, 2791–2807 (2016)
102
J. M. Yoo et al.